在神经元α-SYNuclein生物框架中,PDD和DLBSYNdromes在哪里适合?
David J Irwin1,2,3,4
1LBDA Research Center of Excellence, Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA. dirwin@pennmedicine.upenn.edu.
Journal of neural transmission (Vienna, Austria : 1996)
|December 4, 2025
概括
勒维体疾病 (LBD) 涉及α-synuclein (aSYN) 病理. 新的生物测试有助于诊断,但与帕金森症候群等临床综合征相协调.
科学领域:
- 神经退行性疾病的神经退行性疾病
- 神经病理学神经病理学
- 发现生物标志物的发现.
背景情况:
- 勒维体疾病 (LBD) 是由α-synuclein (aSYN) 蛋白聚合物定义的神经退行性疾病.
- 临床表现,包括患有莱维体 (DLB) 的痴呆症,帕金森病 (PD) 和帕金森病痴呆症 (PDD),重叠显著.
- 由于共同的病理和风险因素,区分PDD和DLB具有挑战性.
研究的目的:
- 审查尸检确认的关于LBDs临床表达的数据.
- 澄清PDD,DLB和混合病理阿尔茨海默病 (AD) 之间的界限.
- 为解释新兴的α-synuclein (aSYN) 生物测试用于LBD分类提供信息.
主要方法:
- 对莱维体疾病 (LBD) 尸检确认的临床数据的审查.
- 临床表现和神经病理发现的分析.
- 检查LBDs和阿尔茨海默病 (AD) 与混合病理之间的重叠.
主要成果:
- PDD和DLB的临床特征在很大程度上重叠,使诊断复杂化.
- 阿尔法-同核素 (aSYN) 病理存在于阿尔茨海默氏病 (AD) 病例的很大一部分中.
- 新兴的生物测试为改善LBD的死前诊断提供了潜力.
结论:
- 将经典的LBD临床综合征与新的生物分类方案相协调至关重要.
- 了解LBD和混合病理AD中的aSYN负担是准确诊断的关键.
- 在外围组织中检测aSYN的进步有望改善LBD的诊断能力.
相关概念视频
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Neural Regulation
43.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.0K
Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Lysosomal Hydrolases
4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K
Amyloid Fibrils
11.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.5K


